The mechanisms by which antidepressants may reduce coronary heart disease risk
Marc J Mathews1, Edward H Mathews2, Leon Liebenberg3
1CRCED Pretoria, North-West University, P.O. Box 11207, Silver Lakes, 0054, South Africa. mjmathews@rems2.com.
Insights
Depression elevates coronary heart disease (CHD) risk, potentially via inflammation and metabolic changes. Selective serotonin reuptake inhibitors (SSRIs) may mitigate this risk by addressing these pathways.
Area of Science:
- Cardiovascular Medicine
- Psychiatry
- Pharmacology
Background:
- Depression is a significant risk factor for coronary heart disease (CHD).
- Pathogenetic mechanisms linking depression and CHD are not fully understood.
- Identifying mediating factors is crucial for CHD prevention strategies.
Purpose of the Study:
- To elucidate the pathogenetic pathways between depression and CHD.
- To explore the potential of selective serotonin reuptake inhibitors (SSRIs) in mitigating CHD risk associated with depression.
Main Methods:
- Utilized an integrated model of CHD to analyze depression's impact.
- Employed biomarker relative risk data to quantify pathogenetic effects.
- Developed a 'connection graph' to visualize interactions between depression, biomarkers, and SSRIs.
Main Results:
- The 'connection graph' illustrated the relationship between depression and CHD biomarkers.
- SSRIs demonstrated potential in decreasing CHD risk.
- Comparison of 'connection graphs' highlighted SSRI mechanisms for risk reduction.
Conclusions:
- Depression's impact on CHD is primarily mediated by increased inflammation and altered metabolism.
- Selective serotonin reuptake inhibitors (SSRIs) show promise in mediating these depression-related CHD effects.
Background:
Depression is known to increase the risk for coronary heart disease (CHD) likely through various pathogenetic actions. Understanding the links between depression and CHD and the effects of mediating these links may prove beneficial in CHD prevention.
Methods:
An integrated model of CHD was used to elucidate pathogenetic pathways of importance between depression and CHD. Using biomarker relative risk data the pathogenetic effects are representable as measurable effects based on changes in biomarkers.
Results:
A 'connection graph' presents interactions by illustrating the relationship between depression and the biomarkers of CHD. The use of selective serotonin reuptake inhibitors (SSRIs) is postulated to have potential to decrease CHD risk. Comparing the 'connection graph' of SSRI's to that of depression elucidates the possible actions through which risk reduction may occur.
Conclusions:
The CHD effects of depression appear to be driven by increased inflammation and altered metabolism. These effects might be mediated with the use of SSRI's.
More Related Videos
08:41Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction
Published on: January 12, 2016
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
01:25Antidepressant Drugs: Overview
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:27Coronary Artery Disease V: Interprofessional Care
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs